Search results
17 mar 2019 · The guideline presents recommendations to prevent CVD that are related to lifestyle factors (eg, diet and exercise or physical activity), other factors affecting CVD risk (eg, obesity, diabetes, blood cholesterol, high BP, smoking, aspirin use), patient-centered approaches (eg, team-based care, shared decision-making, assessment of social ...
- View EPUB
PK ›!JYoa«, mimetypeapplication/epub+zipPK ›!JY...
- Cardiovascular Quality and Outcomes
We showed an association of preeclampsia with future...
- Figure 1
Hypertension is a leading cause of death worldwide, and its...
- Aha/ACC
In 2013, the American Heart Association and American College...
- Table 2
Suboptimal diet is the leading risk factor for death and...
- Low-Calorie Sweetened Beverages and Cardiometabolic Health
In the United States, 32% of beverages consumed by adults...
- Sedentary Behavior and Cardiovascular Morbidity and Mortality
Evidence is accumulating that sedentary behavior might be...
- Seafood Long-Chain N-3 Polyunsaturated Fatty Acids and Cardiovascular Disease
Since the 2002 American Heart Association scientific...
- View EPUB
AHA jointly recommend aspirin therapy (75 to 162 mg/d) for primary prevention of heart disease for persons w/ diabetes age > 40 years or who have additional risk factors for CVD and no contraindications to aspirin therapy. American Stroke Association and AHA further recommend aspirin for cardiovascular prophylaxis among persons whose risk is ...
Aspirin use in males is primarily intended for the prevention of coronary artery disease, while in females, prevention of stroke is the main target. 12 The reason for differences in the effect of aspirin therapy by gender is currently unknown, but evidence suggests that there may be some biological basis for these differences.
23 wrz 2019 · In this article, we revisit the role of aspirin for the primary prevention of cardiovascular diseases by critically reviewing the key scientific literature, highlight key areas of uncertainties for future research, and propose a decisional framework for clinicians to support prescription of aspirin in primary prevention.
1 wrz 2022 · Past primary cardiovascular disease prevention trials of low-dose aspirin have attempted to characterize the clinical benefit (blue line) and risk (red dashed lines) of aspirin therapy by the baseline cardiovascular risks of enrolled populations.
1 maj 2023 · The 2022 US Preventive Services Task Force (USPSTF) recommendation notes that the decision to initiate daily aspirin therapy for primary prevention of cardiovascular disease (CVD) should be made on a case-by-case basis for adults ages 40 to 59 with a 10% or greater 10-year CVD risk.
The benefit of antiplatelet drugs (aspirin and P2Y 12 inhibitors) in reducing mortality and/or new cardiovascular events in patients with prior CVD (secondary prevention) with an acceptable risk of bleeding has been clearly shown (4,5).
